Industry Category
Business Keywords
Company Description
Carmot Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapeutics for individuals living with obesity and diabetes. Now a member of the Roche Group, Carmot Therapeutics is focused on advancing life-changing treatments through pioneering research and development. The company leverages its unique Chemotype Evolution drug discovery platform to identify novel incretin receptor signaling targets.
Carmot Therapeutics is committed to creating a broad pipeline of therapeutics designed to produce substantial weight loss and enhance glycemic control. Their strategic approach and dedication to innovation position them as a key player in the biotechnology sector. Carmot Therapeutics currently has three promising clinical candidates: CT-388, CT-868, and CT-996, each representing significant potential in addressing metabolic disorders.
With its primary location in Berkeley, US, Carmot Therapeutics is poised for continued growth and success within the Roche Group. The company's focus remains steadfast on developing transformative therapies that can significantly improve patient outcomes. We invite the manager of Carmot Therapeutics, Inc. to create a customized and exclusive company showcase and product listing on our platform to further highlight their contributions and capabilities within the biotechnology landscape.
Key Personnel / Employees
Similar Companies
Other organizations in the same industry
SYnAbs
Biotechnology-ResearchGeneration of innovative monoclonal antibodies against haptens & complex transmembrane antigens
Cather Labs
Biotechnology-ResearchBuilding DL-powered software solutions for clinicians to enable early & accurate cancer metastasis d...
Alternative Company Names
This company is also known as